Gut protection by palifermin during autologous haematopoietic SCT

Bone Marrow Transplantation

Volumn 43, Issue 10, 2009, Pages 807-811

  Johansson, J E ^a   Hasseus B ^b,c   Johansson, P ^b   Eklof C ^b   Ohman D ^b   Stockelberg, D ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; C REACTIVE PROTEIN; CARMUSTINE; CIPROFLOXACIN; COTRIMOXAZOLE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; MELPHALAN; PALIFERMIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE MUCOSA PERMEABILITY; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; LYMPHOMA; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PRIORITY JOURNAL; PRURITUS; STOMACH PROTECTION; TASTE DISORDER; TOTAL PARENTERAL NUTRITION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FIBROBLAST GROWTH FACTOR 7; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PARENTERAL NUTRITION; PERMEABILITY; PROTECTIVE AGENTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 67349268433     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.388     Document Type: Article

References (25)

1. Johansson JE, Ekman T. Gastro-intestinal toxicity related to bone marrow transplantation: Disruption of the intestinal barrier precedes clinical findings. Bone Marrow Transplant 1997; 19: 921-925.
2. Fegan C, Poynton CH, Whittaker JA. The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant 1990; 5: 373-377.
3. Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2007. CD001973.
4. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58: 933-939.
5. Farrell CL, Rex KL, Kaufman SA, DiPalma CR, Chen JN, Scully S et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 1999; 75: 609-620.
6. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598.
7. Johansson JE, Abrahamsson H, Ekman T. Gastric emptying afterautologous haemopoietic stem-cell transplantation: A prospective trial. Bone Marrow Transplant 2003; 32: 815-819.
8. Bjarnason I, O'Morain C, Levi AJ, Peters TJ. Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 1983; 85: 318-322.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
10. Aabakken L. Cr-ethylenediaminetetraacetic acid absorption test. Methodologic aspects. Scand J Gastroenterol 1989; 24: 351-358.
11. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and otheror gans in a gnotobiotic mouse model. Infect Immun 1979; 23: 403-411.
12. HollerE, Kolb HJ,MittermullerJ, Kaul M, Ledderose G, Duell T et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890-899.
13. HollerE, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, PechumerH et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation [see comments]. Blood 1990; 75: 1011-1016.
14. Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342-1348.
15. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, orcyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graftversus-host disease in H-2- incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.
16. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
17. Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS et al. Differential roles of IL-1 and TNF-alpha on graftversus-host disease and graft versus leukemia. J Clin Invest 1999; 104: 459-467.
18. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
19. Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLAidentical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308: 302-307.
20. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998; 92: 3960-3967.
21. Hill GR, Cooke KR, Teshima T, Crawford JM, Keith Jr JC, Brinson YS et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998; 102: 115-123.
22. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS et al. Keratinocyte growth factor separates graftversus-leukemia effects from graft-versus-host disease. Blood 1999; 94: 825-831.
23. Johansson JE, Ekman T. Gut toxicity during hemopoietic stem cell transplantation may predict acute graft-versus-host disease severity in patients. Dig Dis Sci 2007; 52: 2340-2345.
24. Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, Federowicz I et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 40: 983-988.
25. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, SilverS et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216-3222.